Do platinum salts fit all triple negative breast cancers?

被引：52

作者：

Gerratana, L. ^{[1
,2
]}

Fanotto, V. ^{[1
,2
]}

Pelizzari, G. ^{[1
,2
]}

Agostinetto, E. ^{[2
]}

Puglisi, F. ^{[1
,2
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Univ Hosp Udine, Dept Med Oncol, Udine, Italy

来源：

CANCER TREATMENT REVIEWS | 2016年 / 48卷

关键词：

BRCAness; Carboplatin; Cisplatin; Triple negative breast cancer; HOMOLOGOUS RECOMBINATION DEFICIENCY; COMPLETE RESPONSE RATES; BASAL-LIKE SUBTYPE; PHASE-III TRIAL; MOLECULAR PORTRAITS; SPORADIC BREAST; OVARIAN-CANCER; DNA-REPAIR; BRCA1; CARBOPLATIN;

D O I：

10.1016/j.ctrv.2016.06.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients. In recent years, several randomised trials have been conducted to evaluate platinum efficacy in both early-stage and advanced TNBC, with conflicting results especially for long-term outcomes. Experimental studies are now focusing on identifying biomarkers of response to help selecting patients who may benefit most from platinum based therapies, including BRCA1/2 mutational status and genomic instability signatures (such as HRD-LOH or HRD-LST scores). A standard therapy for TNBC is still missing and platinum-based regimens represent an emerging therapeutic option for selected patients with a defect in the homologous recombination repair system: The identification of these patients through validated biomarker assays will be crucial to optimize the use of currently approved agents in TNBC. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：34 / 41

页数：8

共 87 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2] A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study [J].

Alba, E. ;

Chacon, J. I. ;

Lluch, A. ;

Anton, A. ;

Estevez, L. ;

Cirauqui, B. ;

Carrasco, E. ;

Calvo, L. ;

Segui, M. A. ;

Ribelles, N. ;

Alvarez, R. ;

Sanchez-Munoz, A. ;

Sanchez, R. ;

Lopez Garcia-Asenjo, J. A. ;

Rodriguez-Martin, C. ;

Escudero, M. J. ;

Albanell, J. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) :487-493

[3] Deciphering Signatures of Mutational Processes Operative in Human Cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Campbell, Peter J. ;

Stratton, Michael R. .

CELL REPORTS, 2013, 3 (01) :246-259

[4] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[5] Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists [J].

Badve, Sunil ;

Dabbs, David J. ;

Schnitt, Stuart J. ;

Baehner, Frederick L. ;

Decker, Thomas ;

Eusebi, Vincenzo ;

Fox, Stephen B. ;

Ichihara, Shu ;

Jacquemier, Jocelyne ;

Lakhani, Sunil R. ;

Palacios, Jose ;

Rakha, Emad A. ;

Richardson, Andrea L. ;

Schmitt, Fernando C. ;

Tan, Puay-Hoon ;

Tse, Gary M. ;

Weigelt, Britta ;

Ellis, Ian O. ;

Reis-Filho, Jorge S. .

MODERN PATHOLOGY, 2011, 24 (02) :157-167

[6]

BENSON JR, 2016, FUTURE ONCOL

[7] Effect of screening and adjuvant therapy on mortality from breast cancer [J].

Berry, DA ;

Cronin, KA ;

Plevritis, SK ;

Fryback, DG ;

Clarke, L ;

Zelen, M ;

Mandelblatt, JS ;

Yakovlev, AY ;

Habbema, JDF ;

Feuer, EJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792

[8] How basal are triple-negative breast cancers? [J].

Bertucci, Francois ;

Finetti, Pascal ;

Cervera, Nathalie ;

Esterni, Benjamin ;

Hermitte, Fabienne ;

Viens, Patrice ;

Birnbaum, Daniel .

INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) :236-240

[9] Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents [J].

Birkbak, Nicolai J. ;

Wang, Zhigang C. ;

Kim, Ji-Young ;

Eklund, Aron C. ;

Li, Qiyuan ;

Tian, Ruiyang ;

Bowman-Colin, Christian ;

Li, Yang ;

Greene-Colozzi, April ;

Iglehart, J. Dirk ;

Tung, Nadine ;

Ryan, Paula D. ;

Garber, Judy E. ;

Silver, Daniel P. ;

Szallasi, Zoltan ;

Richardson, Andrea L. .

CANCER DISCOVERY, 2012, 2 (04) :366-375

[10] Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? [J].

Bonotto, Marta ;

Gerratana, Lorenzo ;

Iacono, Donatella ;

Minisini, Alessandro Marco ;

Rihawi, Karim ;

Fasola, Gianpiero ;

Puglisi, Fabio .

ONCOLOGIST, 2015, 20 (07) :719-724

← 1 2 3 4 5 6 7 8 9 →